LACI3

LACI-3 is a phase III trial which will evaluate the long-term effects of cilostazol and isosorbide mononitrate (ISMN) in preventing adverse outcomes following lacunar stroke and progression of cerebral small vessel disease (SVD).

Chief Investigator: Joanna Wardlaw

Number and location of participating sites (by region/country): N/A

EudraCT number: N/A

ISRCTN number:  N/A

 

Funder: NIHR HTA

Start and End date

Of grant award: 09 January 2024 - 31 December 2028

Of recruitment: N/A

 

Current Status: Open

 

UK GDPR Privacy Statement: As part of Patient Information Sheet

 

ECTU involvement: Health Economics

This article was published on